Jen EY - Search Results

1

Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective.

Baines AC, Yazdy MS, Kasamon YL, Ershler R, Jen EY, Kanapuru B, Richardson NC, Lane A, Carioti T, Theoret MR, Pazdur R, Gormley NJ. Baines AC, et al. Among authors: jen ey. Clin Cancer Res. 2023 Aug 1;29(15):2748-2752. doi: 10.1158/1078-0432.CCR-22-3579. Clin Cancer Res. 2023. PMID: 36892497 Free PMC article.

2

FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease.

Jen EY, Xu Q, Schetter A, Przepiorka D, Shen YL, Roscoe D, Sridhara R, Deisseroth A, Philip R, Farrell AT, Pazdur R. Jen EY, et al. Clin Cancer Res. 2019 Jan 15;25(2):473-477. doi: 10.1158/1078-0432.CCR-18-2337. Epub 2018 Sep 25. Clin Cancer Res. 2019. PMID: 30254079

3

FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy.

Jen EY, Wang X, Li M, Li H, Lee SL, Ni N, Przepiorka D, Vallejo J, Leong R, Ma L, Gehrke BJ, McLamore S, Theoret MR, de Claro RA. Jen EY, et al. Clin Cancer Res. 2022 Jul 15;28(14):2989-2993. doi: 10.1158/1078-0432.CCR-21-4525. Clin Cancer Res. 2022. PMID: 35325108 Free PMC article. Clinical Trial.

4

Considerations for Drug Development in Myelodysplastic Syndromes.

Sekeres MA, Kim N, DeZern AE, Norsworthy KJ, Garcia JS, de Claro RA, Theoret MR, Jen EY, Ehrlich LA, Zeidan AM, Komrokji RS. Sekeres MA, et al. Among authors: jen ey. Clin Cancer Res. 2023 Jul 14;29(14):2573-2579. doi: 10.1158/1078-0432.CCR-22-3348. Clin Cancer Res. 2023. PMID: 36688922 Free PMC article.

5

FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.

Jen EY, Ko CW, Lee JE, Del Valle PL, Aydanian A, Jewell C, Norsworthy KJ, Przepiorka D, Nie L, Liu J, Sheth CM, Shapiro M, Farrell AT, Pazdur R. Jen EY, et al. Clin Cancer Res. 2018 Jul 15;24(14):3242-3246. doi: 10.1158/1078-0432.CCR-17-3179. Epub 2018 Feb 23. Clin Cancer Res. 2018. PMID: 29476018

6

FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.

Jen EY, Gao X, Li L, Zhuang L, Simpson NE, Aryal B, Wang R, Przepiorka D, Shen YL, Leong R, Liu C, Sheth CM, Bowen S, Goldberg KB, Farrell AT, Blumenthal GM, Pazdur R. Jen EY, et al. Clin Cancer Res. 2020 Feb 1;26(3):532-536. doi: 10.1158/1078-0432.CCR-19-2329. Epub 2019 Sep 23. Clin Cancer Res. 2020. PMID: 31548341

7

IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells.

Jen EY, Poindexter NJ, Farnsworth ES, Grimm EA. Jen EY, et al. Melanoma Res. 2012 Feb;22(1):19-29. doi: 10.1097/CMR.0b013e32834d2506. Melanoma Res. 2012. PMID: 22027907 Free PMC article.

8

Sonic hedgehog induces epidermal growth factor dependent matrix infiltration in HaCaT keratinocytes.

Bigelow RL, Jen EY, Delehedde M, Chari NS, McDonnell TJ. Bigelow RL, et al. Among authors: jen ey. J Invest Dermatol. 2005 Feb;124(2):457-65. doi: 10.1111/j.0022-202X.2004.23590.x. J Invest Dermatol. 2005. PMID: 15675968 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters